Literature DB >> 27876967

In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis.

Nagwa Mostafa El-Sayed1, Khadiga Ahmed Ismail2, Abeer Fathy Badawy2, Khaled Fathy Elhasanein3.   

Abstract

Toxoplasma gondii (T. gondii), an intracellular parasite, establishes a chronic infection by forming cysts preferentially in the brain. TNF-α plays an important role in controlling the infection caused by this protozoan. Thus, the blockade of TNF-α could cause reactivation of latent toxoplasmosis infection as well as increase the risk of acute toxoplasmosis. This study evaluated the effect of etanercept, a TNF-α antagonist in reactivation of latent toxoplasmosis compared to the therapeutic effect of sulfadiazine and pyrimethamine in combination on the progress of the disease. A total of 40 laboratory-bred Swiss albino mice were infected with Me49 strain of T. gondii and divided into four groups: infected control group; treated group with sulfadiazine and pyrimethamine; treated group with etanercept and treated group with both etanercept and sulfadiazine and pyrimethamine. The mean number and size of tissue cysts in brain smears of mice of each group were determined and also, serum levels of TNF-α were assessed in different study groups by an enzyme linked immunosorbent assay. The results showed that the mean TNF-α level was significantly different in the treated groups compared to that in infected control group. The highest level of TNF-α was found in the infected controls. After treatment with etanercept alone or combined with sulfadiazine and pyrimethamine, it was significantly decreased. In this study, reactivation of latent toxoplasmosis was observed by a significant increase in the mean number and sizes of Toxoplasma tissue cysts in brains of mice with established chronic toxoplasmosis after treatment with etanercept alone or combined with conventional treatment compared to both untreated chronically infected controls and infected mice treated with sulfadiazine and pyrimethamine. It was concluded that etanercept, a TNF-α antagonist may play a role in reactivation of latent toxoplasmosis. So, serological screening for toxoplasmosis might offer a valuable aid for patients treated with this drug.

Entities:  

Keywords:  Etanercept; Pyrimethamine; Sulfadiazine; TNF-α; Toxoplasma gondii

Year:  2015        PMID: 27876967      PMCID: PMC5118338          DOI: 10.1007/s12639-015-0712-y

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  37 in total

1.  Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.

Authors:  Olgica Djurković-Djaković; Vladimir Milenković; Aleksandra Nikolić; Branko Bobić; Jelica Grujić
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Infliximab and reactivation of cerebral toxoplasmosis.

Authors:  Jeremy D Young; Bradford S McGwire
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

3.  Role of TNF and IL-1 in infections with Toxoplasma gondii.

Authors:  H R Chang; G E Grau; J C Pechère
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

4.  Tissue cyst rupture in mice chronically infected with Toxoplasma gondii. An immunocytochemical and ultrastructural study.

Authors:  D J Ferguson; W M Hutchison; E Pettersen
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

5.  Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells.

Authors:  Erik Jongert; Arnaud Lemiere; Jo Van Ginderachter; Stéphane De Craeye; Kris Huygen; Sushila D'Souza
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

6.  Host Cell Preference of Toxoplasma gondii Cysts in Murine Brain: A Confocal Study.

Authors:  T C Melzer; H J Cranston; L M Weiss; S K Halonen
Journal:  J Neuroparasitology       Date:  2010

7.  Toxoplasmosis.

Authors:  Sandra K Halonen; Louis M Weiss
Journal:  Handb Clin Neurol       Date:  2013

8.  Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation.

Authors:  R T Gazzinelli; I Eltoum; T A Wynn; A Sher
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

Review 9.  Use of etanercept in the treatment of psoriasis and psoriatic arthritis.

Authors:  Brian S Fuchs; Suhail Hadi
Journal:  Rev Recent Clin Trials       Date:  2006-09

10.  Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT).

Authors:  M Gonzalez-Vicent; M A Diaz; J Sevilla; L Madero
Journal:  Ann Hematol       Date:  2003-08-19       Impact factor: 3.673

View more
  4 in total

1.  Transcriptome analysis of ankylosing spondylitis patients before and after TNF-α inhibitor therapy reveals the pathways affected.

Authors:  X B Wang; J J Ellis; D J Pennisi; X Song; J Batra; K Hollis; L A Bradbury; Z Li; T J Kenna; M A Brown
Journal:  Genes Immun       Date:  2017-08-24       Impact factor: 2.676

Review 2.  Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Shayesteh Shahdin; Ahmad Daryani
Journal:  Parasitol Res       Date:  2018-08-08       Impact factor: 2.289

3.  Risk Assessment of Etanercept in Mice Chronically Infected With Toxoplasma gondii.

Authors:  Jing Yang; Luyao Wang; Dongmei Xu; Ding Tang; Senyang Li; Fen Du; Lixia Wang; Junlong Zhao; Rui Fang
Journal:  Front Microbiol       Date:  2018-11-21       Impact factor: 5.640

4.  TNF-TNFR1 Signaling Enhances the Protection Against Neospora caninum Infection.

Authors:  Flávia Batista Ferreira França; Murilo Vieira Silva; Mariana Ferreira Silva; Eliézer Lucas Pires Ramos; Vanessa Dos Santos Miranda; Caroline Martins Mota; Fernanda Maria Santiago; José Roberto Mineo; Tiago Wilson Patriarca Mineo
Journal:  Front Cell Infect Microbiol       Date:  2022-01-07       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.